Navigation Links
MiMedx Reports On Meeting With FDA
Date:10/28/2013

MARIETTA, Ga., Oct. 28, 2013 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company concluded a productive meeting with the Food and Drug Administration ("FDA") earlier today, October 28, 2013.

Parker H. Petit, Chairman and CEO, said, "We were pleased to have had the opportunity to present to the FDA our basis for concluding that our micronized products are minimally manipulated and meet the criteria for regulation solely under Section 361 of the Public Health Service Act and 21 CFR 1271 of the FDA's regulations. The FDA acknowledged that our presentation included new information that they would review and consider, and they committed to responding in a timely fashion.  We hope that, upon further analysis, the FDA will agree with our position.  In all events, we are committed to continuing to work with the Agency to agree on a regulatory solution to ensure that our micronized products are available for patients who can benefit from their clinical effectiveness. These solutions could include, among other things, one or more of the following: labeling changes, changes to the product, changes to the process, or submission of a Biologics License Application." 

About MiMedx 
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies pr
'/>"/>

SOURCE MiMedx, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
2. MiMedx Group Completes $5,000,000 Private Placement
3. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
4. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
5. MiMedx Group Announces 2011 Results
6. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
7. MiMedx Exceeds Revenue Goal for First Quarter of 2012
8. MiMedx Group Announces Record First Quarter Results
9. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
10. MiMedx Group Announces Record Second Quarter Results
11. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 Applied Silicone Corporation, ... for the medical device and critical healthcare market, ... the implantable medical device market. The Dual ... delivering a silicone gel with improved fracture resistance, ... technology consists of two crosslinked networks working in ...
(Date:9/15/2014)... 15 septembre 2014 La deuxième édition ... (semaine internationale sur la sensibilisation au plasma) ... conjointe de la Plasma Protein Therapeutics Association ... , l,IPAW vise à : , ... la collecte du plasma-aphérèse , Reconnaître la ...
(Date:9/15/2014)... -- The second annual International Plasma Awareness Week (IPAW) ... of the Plasma Protein Therapeutics Association (PPTA) ... to: , Raise global awareness about source ... donors in saving and improving lives , Increase ... Member companies are planning a variety ...
(Date:9/14/2014)... UMBC’s Biotechnology Graduate Programs’ ... 21, 2014, from 12:00 to 1:00 p.m. EDT. The ... curriculum and practice-oriented instruction, designed for working professionals. Participants ... advance their career in the biotechnology industry. , If ... , About UMBC’s Biotechnology Graduate Programs, UMBC offers a ...
Breaking Biology Technology:Applied Silicone Launches Silicone Gel System with Dual Matrix Technology 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2
... (Nasdaq: ONXX ) today announced that it ... on Thursday, June 26, at,10:45 a.m. Eastern Time. ... presentation on our website at:, http://www.onyx-pharm.com/wt/page/event_calendar ... on 15 minutes early in order to,register and ...
... in London on Friday, June 20, 2008, NEW ... of the,leading plaintiffs, litigation law firms in America, filed ... a New York City Fire,Department Emergency Medical Technician whose ... EMT Ernest Armstead, was one,of the many brave responders ...
... Calif., June 19 The,Fifth Annual Healthcare Unbound ... Innovation (TCBI), will feature the coming together of,consumer ... help manage,diseases. The Conference will take place at ... will include a diverse representation of the many,business ...
Cached Biology Technology:Weitz & Luxenberg Files Seroquel Diabetes Lawsuit Against AstraZeneca 2Fifth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Disease Management & Wellness Promotion 2Fifth Annual Healthcare Unbound Conference to Focus on Remote Monitoring, Home Telehealth & eHealth for Disease Management & Wellness Promotion 3
(Date:9/15/2014)... the subsequent rapid decrease in the water level of ... square kilometres of new, fertile land in eastern Finland. ... researchers has studied the role that the decrease in ... and humans. After dramatic shifts in the waterways, human ... rise to a new, innovative culture. This stemmed from ...
(Date:9/15/2014)... weighing as much as 170 tons, the blue whale is ... heaviest living thing ever seen on Earth. So there,s no ... fish larvae, which measure millimeters in length and tip the ... Not so fast, says L. Mahadevan, the Lola England de ... and of Physics. , Using simple hydrodynamics, a team ...
(Date:9/15/2014)... cardiovascular disease (CVD) claims 17 million lives each year, ... 9.4 million. 1 New research presented by international ... Montpellier, France on September 15, 2014, suggests that milk ... , At the Milk and Dairy Products in ... risk for hypertension and CVD was examined by Dr. ...
Breaking Biology News(10 mins):The creation of the Vuoksi River preceded a significant cultural shift 2The science behind swimming 2The science behind swimming 3Dairy consumption linked to lower blood pressure and cardiovascular disease risk 2
... research into cheetah cub survival has refuted the theory that ... cannot coexist in conservation areas. The study, published in the ... Kgalagadi Transfrontier Park were seven times more likely to survive ... found to be the cubs, main predatory threat. Previously, ...
... MA -- Researchers at MIT and Brigham and Women,s ... of intestinal stem cells, then stimulate them to develop ... intestinal cells. Using these cells, scientists could develop and ... colitis. The small intestine, like most other body ...
... approach to mapping how proteins interact with each other, ... aid in the design of new drugs for diseases ... artificial amino acids, the Salk scientists determine the detailed ... the molecule that turns it on. The switch--corticotrophin releasing ...
Cached Biology News:Researchers unlock a new means of growing intestinal stem cells 2Researchers unlock a new means of growing intestinal stem cells 3Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3
... Prostaglandin F2α isopropyl ester (15(R)-17-phenyl trinor ... isomer containing both a double bond ... hydroxyl group at C-15. Similar to ... is a potential impurity in most ...
ACS Reagent Grade C 19 H 14 O 5 S Formula Weight: 354.38 PRODUCT SPECIFICATIONS Form: Rust/red crystalline powder Clarity of Solution: Passes test Visual Transition Interval: pH 6.8 - Yellow pH 8.2...
... Mouse Anti Nop1p/Fibrillarin (monoclonal) ... nucleolar protein of bakers yeast, Saccharomyces ... is essential for yeast viability and ... human homologue of Nop1p is fibrillarin ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
Biology Products: